Collegium Pharmaceutical, INC 10-Q quarterly reports

Collegium Pharmaceutical, Inc. reported a net loss for the quarter ended June 30, 2026, with revenues increasing due to the Azstarys acquisition, while operating expenses also rose significantly.

Collegium Pharmaceutical reported a 9% increase in Q1 2026 revenue to $193.5 million, driven by strong performance in Jornay PM and Xtampza ER, while nearing the completion of its AZSTARYS acquisition.

Collegium Pharmaceutical, Inc. reported a significant increase in net income and product revenues for the third quarter of 2025, driven primarily by strong performance of Jornay PM following its acquisition.

Collegium Pharmaceutical reports a significant drop in net income for Q2 2025 despite revenue growth, driven by increased operating expenses and amortization from its Ironshore acquisition.

Collegium Pharmaceutical reports increased revenue in Q1 2025 driven by recent acquisition and product performance, while managing integration and ongoing litigation.

Collegium Pharmaceutical's Q3 2024 results show increased revenue driven by recent acquisition, but also increased expenses and a net income decrease compared to the same period last year.

Collegium Pharmaceutical's Q2 2024 results show a slight revenue increase and a net income of $19.6 million, alongside strategic moves including a new acquisition and debt refinancing.

Collegium Pharmaceutical's first quarter 2024 results show stable revenue with increased profitability, driven by cost management and debt restructuring.